Intraoperative 125I brachytherapy combined with chemotherapy for pancreatic cancer.
- Author:
Dong-min WANG
1
;
Yin-hua LIU
;
Shi-ping YU
;
Xue-ning DUAN
;
Yin-mo YANG
;
Yuan-lian WAN
;
Gang ZHOU
;
Wen-jiang SHEN
Author Information
- Publication Type:Clinical Trial
- MeSH: Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Brachytherapy; Combined Modality Therapy; Deoxycytidine; administration & dosage; analogs & derivatives; Female; Fluorouracil; administration & dosage; Humans; Intraoperative Period; Iodine Radioisotopes; therapeutic use; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; drug therapy; surgery; therapy; Quality of Life; Survival Rate
- From: Chinese Journal of Oncology 2004;26(7):433-436
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy, toxicity and survival of intraoperative 125I brachytherapy combined with chemotherapy for advanced pancreatic cancer.
METHODSThirty-six patients with advanced pancreatic cancer were randomized to two groups: brachy-chemotherapy group (n = 18) and control group (n = 18). For the combined group, intraoperative 125I implantation and gemcitabine, 5-Fu were given. For the control group, intratumoral injection of absolute alcohol was done.
RESULTSThe CR + PR rate of brachy-chemotherapy group was 38.9% with pain relief in 77.8%, while that of control group was 0 with pain relief in 22.2% (P < 0.05). Although there were some toxicity in brachy-chemotherapy group, treatment was well tolerated. The 6-, 12-month survival rates of brachy-chemotherapy group were 71.4% and 21.4% and those of control group were 38.5% and 7.7%, respectively. The median survival time was 10.6 months and 5.2 months for the two groups, between which the difference was significant (P < 0.05).
CONCLUSIONInteroperative 125I brachytherapy combined with chemotherapy for advanced pancreatic cancer can control tumor, relieve pain and improve quality of life. It is safe and effective.
